(Las Vegas, Nevada, USA) DelveInsight’s “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Colorectal Cancer, historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Colorectal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Colorectal Cancer Market Forecast
Some of the key facts of the Colorectal Cancer Market Report:
- The Colorectal Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In 2022, the total incident cases of Colorectal Cancer were around 546,135 cases in the 7MM, which might increase by 2032
- In the 7MM, the highest number of incident cases of Colorectal Cancer were observed in the US, with approximately 151,318 cases in the year 2022
- In October 2022, In order to start a Phase 1 clinical trial for LYL845, Lyell Immunopharma declared that the US Food and Drug Administration (FDA) had approved its Investigational New Drug (IND) application. Patients with relapsed and/or refractory metastatic or locally advanced melanoma will be included in a phase I trial, and enrollment will later be expanded to include patients with non-small cell lung cancer and colorectal cancer
- In 2022, the total incident cases of metastatic colorectal cancer were around 236,639 cases in the 7MM
- Key Colorectal Cancer Companies: Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others
- Key Colorectal Cancer Therapies: Adagrasib (MRTX849), MK-4280A, HMPL-013 (fruquintinib), COSELA (trilaciclib), LUMAKRAS (sotorasib), Onvansertib, NT-I7 (efineptakinalfa), BXQ-350,and others.
Colorectal Cancer Overview
Colorectal cancer (CRC) is the third most common type of cancer, with metastasis being the major cause of death in the majority of patients. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).
Get a Free sample for the Colorectal Cancer Market Report @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
Key benefits of the Colorectal Cancer Market report:
- Colorectal Cancer market report covers a descriptive overview and comprehensive insight of the Colorectal Cancer Epidemiology and Colorectal Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Colorectal Cancer market report provides insights on the current and emerging therapies.
- Colorectal Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Colorectal Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Colorectal Cancer market.
Download the report to understand which factors are driving Colorectal Cancer epidemiology trends @ Colorectal Cancer Market Dynamics
Colorectal Cancer Market
The dynamics of the Colorectal Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“According to the estimates, the highest market size of Colorectal Cancer was found in the United States, followed by Japan and the least was in Spain across the 7MM in 2021. Besides, the upcoming therapies of Colorectal Cancer are expected to combat the current unmet needs faced by the patients with Colorectal Cancer and add to the overall growth of the Colorectal Cancer market size.”
Colorectal Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Colorectal Cancer Epidemiology Segmentation:
The Colorectal Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Colorectal Cancer
- Prevalent Cases of Colorectal Cancer by severity
- Gender-specific Prevalence of Colorectal Cancer
- Diagnosed Cases of Episodic and Chronic Colorectal Cancer
Colorectal Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer market or expected to get launched during the study period. The analysis covers Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Colorectal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Colorectal Cancer market share @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
Colorectal Cancer Therapies and Key Companies
- Adagrasib (MRTX849): Mirati Therapeutics
- MK-4280A: Merck
- HMPL-013 (fruquintinib): Hutchison Medipharma and Takeda
- COSELA (trilaciclib): G1 Therapeutics
- LUMAKRAS (sotorasib): Amgen
- Onvansertib: Cardiff Oncology
- NT-I7 (efineptakinalfa): NeoImmuneTech
- BXQ-350: Bexion Pharmaceuticals
Colorectal Cancer Market Strengths
- Recent advances in pathological staging and identification of the mutational status of KRAS (exon2), BRAF (V600E), and PIK3CA have greatly helped in deciding a path for anti-EGFR therapy of mCRC patients
Scope of the Colorectal Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Colorectal Cancer Companies: Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others, and others
- Key Colorectal Cancer Therapies: Adagrasib (MRTX849), MK-4280A, HMPL-013 (fruquintinib), COSELA (trilaciclib), LUMAKRAS (sotorasib), Onvansertib, NT-I7 (efineptakinalfa), BXQ-350, and others
- Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
- Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Colorectal Cancer Market Access and Reimbursement
Request for free sample page @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market
Colorectal Cancer Market Opportunities
- The recent inclination toward the development of mutation-specific mCRC therapies has led to the approvals of KEYTRUDA, OPDIVO with or without YERVOY and BRAFTOVI in combination with ERBITUX. This clearly, opens up a window for several upcoming mutation-targeted therapies to enter and capture the market
Table of Contents
- Colorectal Cancer Market Report Introduction
- Executive Summary for Colorectal Cancer
- SWOT analysis of Colorectal Cancer
- Colorectal Cancer Patient Share (%) Overview at a Glance
- Colorectal Cancer Market Overview at a Glance
- Colorectal Cancer Disease Background and Overview
- Colorectal Cancer Epidemiology and Patient Population
- Country-Specific Patient Population of Colorectal Cancer
- Colorectal Cancer Current Treatment and Medical Practices
- Colorectal Cancer Unmet Needs
- Colorectal Cancer Emerging Therapies
- Colorectal Cancer Market Outlook
- Country-Wise Colorectal Cancer Market Analysis (2019–2032)
- Colorectal Cancer Market Access and Reimbursement of Therapies
- Colorectal Cancer Market Drivers
- Colorectal Cancer Market Barriers
- Colorectal Cancer Appendix
- Colorectal Cancer Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting